Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)

Clinical Pharmacology and Therapeutics
Magnus ChristensenL Bertilsson

Abstract

Fluvoxamine is metabolized by the polymorphic cytochrome P450 (CYP) 2D6 and the smoking-inducible CYP1A2. Therapeutic doses of fluvoxamine inhibit both CYP1A2 and CYP2C19. In this study we used extensive metabolizers (EMs) and poor metabolizers (PMs) of debrisoquin (INN, debrisoquine) (CYP2D6) and two probes, caffeine (CYP1A2) and omeprazole (CYP2C19), to investigate whether nontherapeutic doses of fluvoxamine inhibit CYP1A2 but possibly not CYP2C19. Single oral doses of 100 mg caffeine and 20 mg omeprazole were given separately to 5 EMs and 5 PMs of debrisoquin to assess the activity of CYP1A2 and CYP2C19, respectively. Initially, a single oral dose of fluvoxamine (25 mg to PMs and 50 mg to EMs) was given, followed by 1 week of daily administration of 25 mg x 2 to EMs and 25 mg x 1 to PMs. Caffeine (day 6) and omeprazole (day 7) were again administered at the steady state of fluvoxamine. Later the study protocol was repeated with a lower dose of fluvoxamine, 10 mg x 2 to EMs and 10 mg x 1 to PMs for 1 week. Concentrations of fluvoxamine, caffeine, omeprazole, and their metabolites were analyzed by HPLC methods in plasma and urine. The kinetics of fluvoxamine were not significantly different in EMs and PMs after a single oral d...Continue Reading

Citations

Mar 5, 2011·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Takenori Niioka
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Jul 9, 2011·Expert Opinion on Drug Metabolism & Toxicology·Stefano PorcelliDiana De Ronchi
Mar 3, 2015·Expert Opinion on Drug Metabolism & Toxicology·Alfredo Carlo AltamuraMassimiliano Buoli
Sep 1, 2005·Basic & Clinical Pharmacology & Toxicology·Mirko S FaberUwe Fuhr
Oct 21, 2005·British Journal of Clinical Pharmacology·Kerry E Culm-MerdekDavid J Greenblatt
Mar 18, 2004·British Journal of Clinical Pharmacology·Norio Yasui-FurukoriTomonori Tateishi
Jan 6, 2004·Fundamental & Clinical Pharmacology·Edoardo SpinaConcetta D'Arrigo
Feb 21, 2006·British Journal of Clinical Pharmacology·Tsukasa UnoTomonori Tateishi
May 7, 2013·Expert Opinion on Drug Metabolism & Toxicology·Vidya PereraAndrew J McLachlan
Jun 15, 2004·Life Sciences·Mitchell D GreenChristopher D King
May 9, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M Miura, T Ohkubo
Apr 15, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Pierre Vandel
Oct 22, 2004·Journal of Clinical Pharmacology·Norio Yasui-FurukoriTomonori Tateishi
Jan 30, 2004·Journal of Clinical Pharmacology·Honghui ZhouJames F McLeod
Nov 15, 2003·Journal of Clinical Pharmacology·Hideto KandaKoichi Otani
Jun 20, 2006·European Journal of Clinical Pharmacology·Agneta WennerholmLars L Gustafsson
Sep 2, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Eveline Jaquenoud SirotPierre Baumann
Dec 14, 2006·Therapeutic Drug Monitoring·Véronique MichaudJacques Turgeon
Apr 27, 2007·Clinical Pharmacology and Therapeutics·R H K ThanacoodyS H L Thomas
May 2, 2007·British Journal of Pharmacology·P K Gillman
Jun 29, 2007·Clinical Pharmacokinetics·Oliver von RichterRobert Hermann
Jul 12, 2008·Molecular Nutrition & Food Research·Brian TomlinsonVivian W Y Lee
Jul 14, 2009·Journal of Clinical Psychopharmacology·Eveline Jaquenoud SirotChin B Eap
Nov 12, 2009·Clinical Pharmacokinetics·Shu-Feng Zhou
Jun 29, 2010·European Journal of Clinical Pharmacology·Guillermo GervasiniJuan Antonio Carrillo
Oct 2, 2012·CNS Drugs·Yumiko AkamineTsukasa Uno
May 19, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·R Scott Obach, Tim F Ryder
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Sep 1, 2006·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Toshiro NiwaAkira Takagi
Sep 15, 2011·Journal of Applied Toxicology : JAT·Kye Sook Lee, Sang Kyum Kim
Mar 5, 2016·Clinical Pharmacokinetics·Laurence GabrielSylvain Goutelle
Jan 28, 2003·Therapeutic Drug Monitoring·Marianne Gex-FabryLuc P Balant
Jul 21, 2016·Toxicological Research·Chang Seon RyuSang Kyum Kim
Nov 13, 2020·JAMA : the Journal of the American Medical Association·Eric J LenzeAngela M Reiersen
Dec 29, 2020·Frontiers in Genetics·Beatriz Carvalho HenriquesKatherine J Aitchison
Feb 20, 2021·Pharmacology & Therapeutics·Aleksandra SzopaPiotr Wlaź

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.